Pharmaxis launches European subsidiary, finds distributor for lung function test

By Angela McDaniels

Seattle, Feb. 6 - Pharmaxis Ltd. has established a subsidiary in the United Kingdom to better access the European market, and Mark Sanders has been appointed European regional director, according to a company news release.

Sanders has managed commercial and business development operations for pharmaceutical and medical device companies in Europe for 25 years, the company said. He was most recently commercial director at Innovata Biomed Ltd., where he was responsible for strategic planning, licensing activity and product launches.

Sanders' first task will be to prepare the markets and partnerships necessary for the commercial launch of Pharmaxis' first product, lung function test Aridol, later this year.

Pharmaxis also announced that it has signed a five-year contract with Zurich, Switzerland-based respiratory and allergy pharmaceutical company Trimedal AG for the distribution and marketing of Aridol in Switzerland and Liechtenstein.

''This is our second marketing and distribution agreement for Aridol," chief executive officer Alan Robertson said in the release.

"Trimedal has valuable experience in the markets where Aridol will be sold and distributes a complementary product range. Their respiratory franchise, market strength and the resources they will commit to Aridol were the prime factors in selecting them as a partner.''

Pharmaxis said it lodged its application for regulatory and marketing approval of Aridol with the Swedish Medical Products Agency in May 2005 and anticipates registration for Aridol during the first half of 2006.

Aridol is a lung function test designed to identify patients with active airway inflammation, such as that which occurs in asthma. It will help doctors more accurately determine the severity of a patient's disease and allow prescription of the right amount of medication, the company said.

Pharmaxis is a specialist pharmaceutical company based in Sydney, Australia, that researches, develops and commercializes therapeutic products for chronic respiratory and autoimmune diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.